Achillion

Alexion Ends Rare Kidney Disease Program Following Poor Data
Alexion Ends Rare Kidney Disease Program Following Poor Data
BioSpace
Alexion Pharmaceuticals
Achillion
M&A
kidney disease
Flag link:
Alexion dumps ex-Achillion C3G program after seeing phase 2 data
Alexion dumps ex-Achillion C3G program after seeing phase 2 data
Fierce Biotech
Alexion
Achillion
M&A
clinical trials
Flag link:
After Alexion buyout, ex-Achillion nephrology lead jumps ship to Gemini Therapeutics
After Alexion buyout, ex-Achillion nephrology lead jumps ship to Gemini Therapeutics
Fierce Biotech
Alexion Pharma
Achillion
nephrology
Gemini Therapeutics
Flag link:
Alexion to Buy Achillion in $930M Marriage of Rare Disease Drug Firms
Alexion to Buy Achillion in $930M Marriage of Rare Disease Drug Firms
Xconomy
Alexion Pharmaceuticals
Achillion
M&A
PNH
danicopan
Soliris
Flag link:
After rocky hep C path, Achillion finds surer footing with FDA breakthrough status
After rocky hep C path, Achillion finds surer footing with FDA breakthrough status
Endpoints
Achillion
FDA
paroxysmal nocturnal hemoglobinuria
Soliris
PNH
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs
Yahoo/Benzinga
biotech
Achillion
Sesen Bio
The Medicines Company
Amgen
Daiichi Sankyo
earnings
Flag link:
Achillion Meets Enrollment Target in Kidney Disease Studies
Achillion Meets Enrollment Target in Kidney Disease Studies
Yahoo/Zacks.com
Achillion
ACH-4471
kidney disease
clinical trials
Flag link:
Why Achillion Pharmaceuticals, Inc. Stock Spiked Monday
Why Achillion Pharmaceuticals, Inc. Stock Spiked Monday
Motley Fool
Achillion
Europe
kidney disease
ACH-4471
Flag link:
J&J scraps a multibillion-dollar hepatitis C program after rivals divvy up the market
J&J scraps a multibillion-dollar hepatitis C program after rivals divvy up the market
Endpoints
JNJ
Achillion
hepatitis C
odalasvir
ACH-3102
Flag link:
J&J advances through PhII with a promising hep C triple and 100% cure rate
J&J advances through PhII with a promising hep C triple and 100% cure rate
Endpoints
JNJ
hepatitis C
clinical trials
odalasvir
AL-335
Olysio
Achillion
Flag link:
8 Major FDA Decisions and Trial Results to Watch for in September
8 Major FDA Decisions and Trial Results to Watch for in September
24/7 Wall St
FDA
Achillion
odalasvir
AL-335
simeprevir
Amarin
Vascepa
Array Biopharma
binimetinib
Mast Therapeutics
vepoloxamer
Novavax
Threshold Pharmaceuticals
tarloxotinib
Flag link:
3 Biotechs Expecting Market-Moving Trial Results Soon
3 Biotechs Expecting Market-Moving Trial Results Soon
Motley Fool
biotech
Ophthotech
Achillion
Kite Pharma
odalasvir
JNJ
Fovista
KTE-C19
Flag link:
Achillion's Pipeline Strengthens, With Near-Term Potential Catalysts
Achillion's Pipeline Strengthens, With Near-Term Potential Catalysts
Seeking Alpha
Achillion
ACH-4471
JNJ
hepatitis C
Flag link:
Buying These 2 Drug Developers Would Make a Lot of Sense for Johnson & Johnson
Buying These 2 Drug Developers Would Make a Lot of Sense for Johnson & Johnson
Motley Fool
JNJ
drug development
M&A
Geron
Achillion
Flag link:
3 Small-Cap Biotech Stocks With Big News Coming in 2016
3 Small-Cap Biotech Stocks With Big News Coming in 2016
Motley Fool
biotech
Ophthotech
Fovista
andexanet alfa
Portola Pharmaceuticals
ACH-3102
Achillion
Flag link:
4 Key FDA Decisions Expected By Year End
4 Key FDA Decisions Expected By Year End
24/7 Wall St
FDA
Achillion
hepatitis C
Biocryst
OPuS-2
BCX4161
Tetraphase Pharmaceuticals
Lucitanib
Clovis Oncology
Flag link:
Is Gilead Sciences' Dominance in Hepatitis C Unstoppable?
Is Gilead Sciences' Dominance in Hepatitis C Unstoppable?
Motley Fool
Gilead Sciences
hepatitis C
Harvoni
Sovaldi
AbbVie
Viekira Pak
Achillion
Flag link:
Johnson & Johnson And Achillion Pharmaceuticals May Offer Fastest 100% Cure With Their HCV Combo
Johnson & Johnson And Achillion Pharmaceuticals May Offer Fastest 100% Cure With Their HCV Combo
Bidness, ETC
JNJ
Achillion
hepatitis C
Sovaldi
Gilead Sciences
ACH-3102
odalasvir
Flag link:
What Will Gilead Buy Next? 4 Possible Targets
What Will Gilead Buy Next? 4 Possible Targets
Investors.com
Gilead Sciences
M&A
Incyte
Vertex Pharmaceuticals
Bristol-Myers Squibb
Achillion
Flag link:
5 Drugs That Investors May Be Undervaluing
5 Drugs That Investors May Be Undervaluing
Motley Fool
Amicus Therapeutics
Galafold
Receptos
ozanimod
GS-5816
Gilead Sciences
ACH-3102
Achillion
Ophthotech
Fovista
Flag link:

Pages